Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVX70120
- Development stage
- Phase 1
- Lead developer
- AstriVax Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
AVX70120 is a prophylactic vaccine candidate developed by AstriVax for the prevention of yellow fever. It is built on the company's proprietary Launch-iT platform, which utilizes a thermostable, plug-and-play technology derived from research at the KU Leuven Rega Institute. The platform is designed to create vaccines that do not require a cold chain and provide long-lasting protection. AVX70120 is currently being evaluated in a Phase 1 clinical trial to assess its safety, reactogenicity, and immunogenicity in healthy adults.
- Other names
- AVX70120AVX-70120AVX 70120
Beyond the preview
Go deeper on AVX70120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVX70120.